311 related articles for article (PubMed ID: 35411506)
21. Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery.
Loryan I; Sinha V; Mackie C; Van Peer A; Drinkenburg W; Vermeulen A; Morrison D; Monshouwer M; Heald D; Hammarlund-Udenaes M
Pharm Res; 2014 Aug; 31(8):2203-19. PubMed ID: 24623476
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy.
Hu Y; Girdenyté M; Roest L; Liukkonen I; Siskou M; Bällgren F; Hammarlund-Udenaes M; Loryan I
Fluids Barriers CNS; 2024 Feb; 21(1):13. PubMed ID: 38331886
[TBL] [Abstract][Full Text] [Related]
23. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
[TBL] [Abstract][Full Text] [Related]
24. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Fridén M; Winiwarter S; Jerndal G; Bengtsson O; Wan H; Bredberg U; Hammarlund-Udenaes M; Antonsson M
J Med Chem; 2009 Oct; 52(20):6233-43. PubMed ID: 19764786
[TBL] [Abstract][Full Text] [Related]
25. Revisiting atenolol as a low passive permeability marker.
Chen X; Slättengren T; de Lange ECM; Smith DE; Hammarlund-Udenaes M
Fluids Barriers CNS; 2017 Oct; 14(1):30. PubMed ID: 29089037
[TBL] [Abstract][Full Text] [Related]
26. Multiple drug transporters contribute to the brain transfer of levofloxacin.
Cen Y; Shan Y; Zhao J; Xu X; Nie Z; Zhang J
CNS Neurosci Ther; 2023 Jan; 29(1):445-457. PubMed ID: 36253925
[TBL] [Abstract][Full Text] [Related]
27. Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation.
Anoshchenko O; Storelli F; Unadkat JD
Drug Metab Dispos; 2021 Oct; 49(10):919-928. PubMed ID: 34426410
[TBL] [Abstract][Full Text] [Related]
28. Practical Application of Rodent Transporter Knockout Models to Assess Brain Penetration in Drug Discovery.
Eneberg E; Jones CR; Jensen T; Langthaler K; Bundgaard C
Drug Metab Bioanal Lett; 2022; 15(1):12-21. PubMed ID: 35196975
[TBL] [Abstract][Full Text] [Related]
29. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier.
Mangas-Sanjuan V; González-Álvarez I; González-Álvarez M; Casabó VG; Bermejo M
Mol Pharm; 2013 Oct; 10(10):3822-31. PubMed ID: 23977999
[TBL] [Abstract][Full Text] [Related]
30. Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.
Morales JF; Montoto SS; Fagiolino P; Ruiz ME
Mini Rev Med Chem; 2017; 17(3):247-257. PubMed ID: 27739359
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins.
Yoshikado T; Toshimoto K; Nakada T; Ikejiri K; Kusuhara H; Maeda K; Sugiyama Y
Drug Metab Dispos; 2017 Jul; 45(7):779-789. PubMed ID: 28468836
[TBL] [Abstract][Full Text] [Related]
32. How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Le J; Talele S; Sarkaria JN; Elmquist WF
Pharm Res; 2023 Nov; 40(11):2731-2746. PubMed ID: 37589827
[TBL] [Abstract][Full Text] [Related]
33. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine.
Boström E; Hammarlund-Udenaes M; Simonsson US
Anesthesiology; 2008 Mar; 108(3):495-505. PubMed ID: 18292687
[TBL] [Abstract][Full Text] [Related]
34. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
Reichel A
Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
[TBL] [Abstract][Full Text] [Related]
35. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
[TBL] [Abstract][Full Text] [Related]
36. The Brain Exposure Efficiency (BEE) Score.
Gupta M; Bogdanowicz T; Reed MA; Barden CJ; Weaver DF
ACS Chem Neurosci; 2020 Jan; 11(2):205-224. PubMed ID: 31815431
[TBL] [Abstract][Full Text] [Related]
37. Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model.
Kosugi Y; Mizuno K; Santos C; Sato S; Hosea N; Zientek M
AAPS J; 2021 May; 23(4):72. PubMed ID: 34008121
[TBL] [Abstract][Full Text] [Related]
38. Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation.
Varadharajan S; Winiwarter S; Carlsson L; Engkvist O; Anantha A; Kogej T; Fridén M; Stålring J; Chen H
J Pharm Sci; 2015 Mar; 104(3):1197-206. PubMed ID: 25546343
[TBL] [Abstract][Full Text] [Related]
39. On the rate and extent of drug delivery to the brain.
Hammarlund-Udenaes M; Fridén M; Syvänen S; Gupta A
Pharm Res; 2008 Aug; 25(8):1737-50. PubMed ID: 18058202
[TBL] [Abstract][Full Text] [Related]
40. A physiologically based modeling strategy during preclinical CNS drug development.
Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
Mol Pharm; 2014 Mar; 11(3):836-48. PubMed ID: 24446829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
